Seres Therapeutics, Inc. (MCRB): Nasdaq/NYSE listing notice — Seres Therapeutics receives Nasdaq delisting notice for bid price below $1.00

Seres Therapeutics, Inc.

Received Nasdaq letter on April 19, 2024, for bid price closing below $1.00 for 30 consecutive business days.
Has until October 16, 2024 (180 days) to regain compliance; stock must close at $1.00+ for 10 consecutive days.
May consider reverse stock split to cure deficiency; no assurance of regaining compliance.
Stock continues trading under MCRB on Nasdaq Global Select Market during cure period.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Seres Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

April 19, 2024, Seres Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The letter has no immediate effect on the listing of the Common Stock on T

View on SEC.gov

Browse all listing & compliance notices →

Seres Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-105862

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.